jRCT2021230013CompletedNot Applicable
A multicenter, randomized, open-label, parallel-group study of EN-P11 in patients with enteral tube feeding.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 110
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized Controlled Trial
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment Purpose
- Masking
- Open(masking Not Used)
Eligibility Criteria
- Ages
- 18age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •Receiving enteral feeding via enteral tube.
- •Patients being hospitalized.
- •Aged 18 years or older at the time of obtaining informed consent.
- •4.Written informed consent of free will has been obtained.
Exclusion Criteria
- •History of hypersensitivity to any ingredients of study drugs.
- •History of allergy to milk protein.
- •Pateints with Ileus.
- •No residual intestinal function.
- •Severe liver or renal dysfunction (example: acute or chronic renal failure, or cirrhosis).
- •Abnormalities in carbohydrate metabolism including severe diabetes mellitus.
- •Congenital abnormalities in amino acid metabolism.
- •Severe heart disease (example: myocardial infarction), severe hematological disorder (example: aplastic anemia), inflammatory bowel disease, pneumonia, serious diarrhea (example: frequent watery diarrhea), and malignant tumor.
- •Pregnant or wish to become pregnant.
- •History of resection of gastrointestinal tract (esophagus, stomach or intestines) within 1year before obtaining informed consent , except for slight removal like polyp or appendectomy.
- •Taking a diet (regular diet, swallowing control diet, blender diet or paste diet).
- •Difficult to take required amount of blood sample for clinical trial.
- •Participated in clinical trial or the use of unapproved drugs within 24weeks before obtaining informed consent.
- •History of surgery within 4weeks before registration (in case of gastrostomy, minor surgery such as debridement for pressure ulcers, within 2weeks before registration).
- •History of fasting for 3or more consecutive days within 4weeks before registration.
- •Screening test 1
- •Serum AST :100 U/L or more
- •Serum ALT :113 U/L or more
- •Serum Cre :2 mg/dL or more
- •Blood HbA1c :8.0% or more
- •Blood WBC :over 9000/uL
- •Serum CRP :3.0 mg/dL or higher
- •Urinary HCG :positive (not required if menopause has been confirmed, there is no possibility of pregnancy due to surgical procedures in the past, or if it can be confirmed that there has been no sexual activity for more than 1year)
- •Screening test 2
- •Body temperature :37.5 degrees Celsius or higher (on registration day).
- •Judged by investigator to be excluded.
Outcomes
Primary Outcomes
-
transthyretin, retinol-binding protein, transferrin
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Recruiting
Phase 3
A multicenter, randomized, open-label, parallel-group study of EN-P11 in patients with enteral tube feeding.JPRN-jRCT2021230013Michio Maruyama110
Completed
Not Applicable
IDPN-2Chronic kidney diseaseJPRN-jRCTs031220296Kanno Yoshihiko40
Active, not recruiting
Not Applicable
Open-label, randomized, active-controlled study of Levetiracetam (LEV) used as monotherapy in patients with Partial-Onset SeizuresEpilepsyPartial SeizuresMedDRA version: 18.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-004586-84-Outside-EU/EEACB Pharma SA436
Active, not recruiting
Not Applicable
A randomized, open-label, multicenter, parallel-group study to compare the efficacy, safety and resource utilization of a remifentanil/propofol analgosedation regimen versus a sufentanyl/propofol analgosedation regimen in ventilated patients under intensive medical care with an expected duration of analgosedation of up to 7 daysVentilated patients under intensive medical care with an expected duration of analgosedation of up to 7 daysEUCTR2006-001276-20-DEGlaxoSmithKline GmbH & Co. KG164
Active, not recruiting
Not Applicable
An open-label, randomized, multicenter, parallel-group study to demonstrate correction of anemia using once every four weeks subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis - CORDATUSChronic renal anemiaMedDRA version: 8.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaEUCTR2006-001434-41-HUF. Hoffmann-La Roche Ltd300